Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562755 · ClinicalTrials.gov registry record · Phase 3
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
A Phase 3 study, sponsored by SillaJen.
- Completed
- Registry status
- Phase 3
- Development phase
- 459
- Enrollment target
NCT02562755 is a Phase 3 study that has completed, run by SillaJen. The registered enrollment target is 459 participants.
The verdict
NCT02562755, a Phase 3 study, has completed, sponsored by SillaJen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 459 participants
- Enrollment target
Study Summary
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
Interventions
- DRUG Sorafenib
- BIOLOGICAL Pexastimogene Devacirepvec (Pexa Vec)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2015-10 |
| Est. Completion | 2020-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02562755
The ClinicalTrials.gov registry entry for NCT02562755 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SillaJen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT02562755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02562755 about?
NCT02562755 is a clinical study titled "Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone". This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
What is the current status of trial NCT02562755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 459 participants. The study started on 2015-10. Estimated completion is 2020-07.
What interventions are being tested in trial NCT02562755?
The interventions under investigation include: Sorafenib (DRUG), Pexastimogene Devacirepvec (Pexa Vec) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02562755?
This trial is sponsored by SillaJen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.